INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Recent Advancement in Management of H. Pylori Induced PUD

Chordiya Divya*, Vaishnavi Bansode, Rohit Bhosale, Azeem Mannan Bagwan

Shivlingeshvar College Of Pharmacy Almala.

ARTICLE INFO

Published: 08 Mar. 2025
Keywords:
Anti-Helicobacter pylori activity, Alternative therapies, Botanical extracts, Artificial intelligence AI, Natural products.
DOI:
10.5281/zenodo.14993138

ABSTRACT

Helicobacter pylori (H. pylori) infection is a significant global health issue, affecting nearly half of the world's population. This bacterium colonizes the stomach lining and is linked to various gastrointestinal disorders, including chronic gastritis, peptic ulcers, and gastric cancer. The standard treatment typically involves a combination of antibiotics and proton pump inhibitors (PPIs); however, the growing prevalence of antibiotic-resistant strains has made treatment more challenging. Advances in diagnostic techniques now include non-invasive testing methods and serological biomarkers. While conventional antibiotic and PPI therapy remains the primary approach, there is increasing interest in alternative treatments such as botanical extracts, natural compounds, and traditional medicine. Researchers have also investigated the role of probiotics, phage therapy, and emerging antibiotics like rifabutin and furazolidone in combating H. pylori. Additionally, artificial intelligence (AI) has shown potential in enhancing diagnosis and treatment strategies. AI-powered screening has helped identify novel botanical compounds with anti-H. pylori properties, offering new therapeutic possibilities. Furthermore, AI-driven methods can enhance diagnostic precision and treatment efficacy. Although these alternative approaches appear promising, further studies are essential to determine their effectiveness, safety, and optimal dosages. Innovative treatments, including phage therapy and next-generation antibiotics, may provide viable solutions to combat antimicrobial resistance in H. pylori infections.

INTRODUCTION

Helicobacter pylori (H. pylori) is a spiral-shaped, microaerophilic, Gram-negative bacterium that thrives in harsh conditions and colonizes the human gastric mucosa. It is linked to several gastrointestinal disorders, including chronic gastritis, peptic ulcers, and gastric cancer. H. pylori infection is widespread, affecting nearly half of the global population. The bacterium establishes itself in the stomach lining, triggering the release of inflammatory cytokines, which leads to persistent inflammation and tissue damage.

***Corresponding Author:** Chordiya Divya
Address: Shivlingeshvar College Of Pharmacy Almala.
Email ✉: divyarchordiya@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Common symptoms of H. pylori infection include abdominal pain, bloating, nausea, vomiting, and loss of appetite. If untreated, the infection can result in serious complications such as peptic ulcers, gastric cancer, and lymphoma (Figure. Th The standard treatment for Helicobacter pylori (H. pylori) infection typically involves a combination of antibiotics and proton pump inhibitors (PPIs). However, the extensive use of antibiotics has contributed to the emergence of antibiotic-resistant H. pylori strains, complicating treatment efforts. Additionally, prolonged PPI use has been linked to adverse effects, including an increased risk of infections, kidney disease, and bone fractures. Research has provided valuable insights into the pathogenesis of H. pylori infection, highlighting the significance of virulence factors such as CagA and VacA, as well as the bacterium's interaction with the host immune system. Recent advancements in H. pylori diagnostic techniques have introduced non-invasive methods, including stool antigen and breath tests, both of which demonstrate high sensitivity and specificity. Furthermore, recent studies have investigated the potential of serological biomarkers, such as anti-H. pylori antibodies, as diagnostic tools for detecting infections.



(a) *H. pylori* entry, adherence to gastric mucosa (b) exploitation of human immune system (c) multiplication, tissue damage and transmission to susceptible host (d) sign, symptoms and complication of *H. pylori* infection.

Interest in alternative therapies for *Helicobacter pylori* (*H. pylori*) infection has been increasing, particularly in the use of botanical extracts and natural compounds. Advances in artificial intelligence (AI) and high-throughput screening technologies have facilitated the discovery of novel botanical extracts with potential anti-*H. pylori* properties. AI-assisted screening has proven valuable in analyzing large datasets efficiently, enabling the identification of promising therapeutic candidates with high precision. Several natural extracts have demonstrated antibacterial effects against *H. pylori* and anti-inflammatory properties. For example, garlic extract has been shown to inhibit *H. pylori* growth and reduce gastric mucosal inflammation. Ginger extract also exhibits anti-*H. pylori* activity and can help mitigate *H. pylori*-induced inflammation. Green tea extract has been found to suppress *H. pylori* proliferation while reducing inflammation in the gastric lining. Additionally, turmeric extract possesses anti-*H. pylori* properties and may help alleviate oxidative stress and inflammation caused by the infection. Other natural substances have also shown potential in managing *H. pylori* infections. Honey has demonstrated antibacterial activity against *H. pylori*, while propolis has been found to inhibit bacterial growth and reduce inflammation. Probiotics, particularly strains from the *Lactobacillus* and *Bifidobacterium* genera,

have exhibited anti-*H. pylori* effects and may contribute to reducing the risk of related gastrointestinal diseases. Alongside natural products, traditional medicine has also been explored as a treatment for *Helicobacter pylori* (*H. pylori*) infection. Traditional Chinese remedies, including Qingre Huoxue decoction and Banxia Xiexin decoction, have demonstrated antibacterial activity against *H. pylori* and have been shown to reduce inflammation caused by the infection. Similarly, traditional Korean medicines such as Yukgunja-Tang and Pyungwi-san have exhibited anti-*H. pylori* properties and have been reported to alleviate symptoms associated with the infection Althoughernative therapies hold potential in *H. pylori* management, further investigation is necessary to establish their efficacy and safety. Clinical trials are essential to validate their effectiveness, determine optimal dosages and treatment durations, and assess any possible side effects. Additionally, research should explore the potential of combining these therapies with antibiotics or other treatment strategies to enhance their effectiveness. A recent study evaluated the combination of IgY-*H. pylori* with bismuth-based quadruple therapy for *H. pylori* eradication. The results indicated that while the combination therapy was comparable in effectiveness to bismuth-based quadruple therapy alone, it provided better symptomatic relief and had fewer adverse effects. The researchers suggested that this approach could serve as a viable option for rescue therapy in cases where standard treatments have failed. This study was conducted as a single-center, randomized, controlled trial. The treatment of Helicobacter pylori (H. pylori) infection typically involves a combination of antibiotics and acid suppression therapy. However, the rise of antibiotic-resistant strains has contributed to a decline in eradication rates, prompting the need for alternative treatment strategies. Recent research has explored novel approaches, including sequential therapy, concomitant therapy, hybrid therapy, and high-dose dual therapy. Additionally, probiotics and fecal microbiota transplantation (FMT) have been investigated as potential therapeutic options. To address antibiotic resistance, alternative antibiotics such as rifabutin and furazolidone have been introduced, alongside innovative therapies like probiotics and phage therapy. Phage therapy utilizes bacteriophages—viruses that specifically target and eliminate bacteria—as a potential method for reducing H. pylori colonization. Studies in animal models have demonstrated promising results, suggesting that phage therapy could be an effective alternative treatment. Probiotics, particularly those containing Lactobacillus and Bifidobacterium strains, have also been shown to enhance H. pylori eradication rates while minimizing treatment-related side effects. Similarly, rifabutin, a broad-spectrum antibiotic, has demonstrated success in treating antibiotic-resistant H. pylori infections, with studies reporting high eradication rates. Furazolidone, another promising antibiotic, has proven effective in cases of metronidazole resistance, further expanding the available treatment options for H. pylori infection.

Recent Advances in Diagnostic Tools for *H. pylori* Infection

A variety of diagnostic tests are available for detecting *Helicobacter pylori* (*H. pylori*) infection, each with distinct benefits, drawbacks, and limitations. The selection of a diagnostic method depends on factors such as availability, laboratory resources, and the patient's clinical condition. Diagnostic approaches are generally classified as either non-invasive or invasive. Non-invasive techniques include breath tests, stool antigen tests, and serological assays. In contrast, invasive methods require endoscopic procedures and may involve histological examination, rapid urease testing, bacterial culture, or polymerase chain reaction (PCR) analysis, as illustrated in Figure 2.



Stool Antigen Tests

Stool antigen tests are non-invasive diagnostic methods that identify H. pylori antigens in stool samples. Research indicates that these tests exhibit high sensitivity and specificity, making them a reliable alternative to invasive techniques like endoscopy.

Serological Biomarkers

Serological biomarkers, including immunoglobulin G (IgG) antibodies, have been explored as potential indicators for detecting H. pylori infection. Studies suggest that these biomarkers offer high sensitivity and specificity, providing a non-invasive option for diagnosis.

Breath Tests

Breath tests work by administering a labeled substrate, followed by measuring labeled carbon dioxide (CO_2) in exhaled air. These tests have been shown to be highly sensitive and specific, making them an effective tool for diagnosing H. pylori infection.

Rapid Urease Tests

Rapid urease tests detect the presence of urease enzyme produced by H. pylori in biopsy samples. Research has demonstrated that these tests are both fast and accurate, offering a highly sensitive and specific diagnostic approach.

Endoscopic Imaging Techniques

Advanced endoscopic imaging methods, including narrow-band imaging and confocal laser endomicroscopy, have shown significant potential in diagnosing H. pylori infection. Studies suggest that these techniques produce high-resolution images of the gastric mucosa, allowing for precise detection of H. pylori presence.

Molecular Diagnostic Tests

Molecular testing methods, such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP), have been explored as reliable diagnostic options for H. pylori infection. Research indicates that these molecular approaches offer high sensitivity and specificity, enabling accurate detection of H. pylori in clinical samples.

Recent Advances in H. pylori Therapy

The standard treatment for Helicobacter pylori (H. pylori) infection involves a combination of antibiotics and acid-suppressing medications. However, increasing antibiotic resistance has necessitated the development of alternative

therapeutic approaches. One such advancement is the use of novel antibiotic combinations. Research has demonstrated that combinations including clarithromycin, amoxicillin, and metronidazole can effectively eradicate H. pylori. Additionally, alternative antibiotic regimens, such as those incorporating rifabutin and levofloxacin, have shown promising results in clinical trials.

Probiotics and H. pylori Treatment

Probiotics, which are beneficial microorganisms, have been explored as a complementary treatment for H. pylori infections. Studies indicate that probiotics can help reduce bacterial load, alleviate gastric inflammation, and restore gut microbiota balance, which may be disrupted by antibiotic treatment.

Herbal Medicines as a Therapeutic Option

Herbal remedies have long been utilized for gastrointestinal disorders, and recent research suggests that certain plant-based compounds may aid in H. pylori treatment. Substances such as licorice and green tea have demonstrated potential in reducing bacterial colonization and inflammation within the stomach.

Immunomodulators in H. pylori Therapy

Immunomodulators, which influence the body's immune response, are also being investigated as potential treatments for H. pylori infections. Compounds like vitamin D and interleukin-10 have shown effectiveness in modulating immune reactions to the bacterium, thereby aiding in its control. A notable study examined the combination of Bifidobacterium breve and Trigonella foenum-graecum (fenugreek) extract, finding that the mixture was more effective in combating H. pylori-induced inflammation than either component alone. This combination was observed to reduce gastric mucosal damage by inhibiting H. pylori adhesion to the stomach lining while enhancing mucin secretion. These findings highlight the potential of probiotic and herbal formulations as therapeutic agents for H. pylori-associated gastric conditions, including ulcers.

Medicinal Properties of Flavonols

Flavonols, a class of natural compounds that includes quercetin, myricetin, kaempferol, fisetin, rutin, and astragalin, have been recognized for their diverse therapeutic properties. These bioactive compounds exhibit antibacterial, antiviral, and anticancer activities, making them valuable in the treatment of various diseases. Among them, kaempferol has demonstrated strong antibacterial effects against *Helicobacter pylori*, a pathogen associated with gastric cancer. Additionally, quercetin functions as a potent antioxidant by inhibiting multiple enzymes. Research also suggests that kaempferol contributes to pancreatic beta-cell survival and prevents apoptosis, highlighting its potential as an antidiabetic agent. Furthermore, flavonols have shown promise in antiviral therapy by blocking viral entry into host cells and inhibiting replication, positioning them as alternative treatments for infectious diseases. Collectively, these findings support the therapeutic significance of flavonols in managing a range of health conditions.

Limitations of Current *H. pylori* Therapies

While the conventional treatment for *H. pylori* infection involves a combination of antibiotics and proton pump inhibitors (PPIs), several challenges limit its effectiveness, including antibiotic resistance, adverse side effects, and patient non-compliance.

- **Antibiotic Resistance:** One of the major hurdles in *H. pylori* treatment is the emergence of antibiotic-resistant strains. The extensive use of antibiotics has led to a decline in treatment efficacy, particularly in cases of clarithromycin resistance, which has significantly reduced the success of first-line therapies.

- **Adverse Effects:** The administration of antibiotics and PPIs is often associated with side effects such as nausea, diarrhea, vomiting, abdominal pain, and allergic reactions. These adverse effects can reduce patient adherence to treatment and contribute to therapeutic failure.
- **Patient Non-Compliance:** The complexity and prolonged duration of *H. pylori* treatment regimens can lead to difficulties in adherence. Patients may forget doses or discontinue therapy due to side effects, increasing the risk of incomplete eradication and further antibiotic resistance.

Outlook on the Role of Botanical Extracts in H. pylori Treatment

Antimicrobial Properties

Botanical extracts are rich in bioactive compounds with antimicrobial properties that can inhibit Helicobacter pylori growth. Notable compounds include berberine, curcumin, mastic gum, licorice, and cranberry-derived compounds. These substances can interfere with H. pylori's cellular integrity and metabolic processes, ultimately leading to bacterial eradication. Research suggests that berberine, when combined with amoxicillin, exhibits a synergistic effect in suppressing H. pylori growth, highlighting the potential of botanical extracts in combination therapies.

Anti-Inflammatory Effects

Beyond their antimicrobial action, botanical extracts also exhibit anti-inflammatory properties, which can help mitigate the gastric inflammation associated with H. pylori infection. Curcumin and licorice, for instance, have been shown to reduce the secretion of inflammatory cytokines in gastric epithelial cells infected with H. pylori. Similarly, mastic gum has demonstrated anti-inflammatory benefits by lowering proinflammatory cytokine levels in H. pylori-infected gastric tissue. Additionally, a combination of mastic gum and vitamin C has been found to significantly reduce inflammation in individuals with H. pylori infection.

Potential in Combination Therapy

Integrating botanical extracts with conventional antibiotics may enhance treatment outcomes and lower the likelihood of antibiotic resistance. A recent meta-analysis revealed that supplementing standard H. pylori therapy with herbal medicine led to improved eradication rates and fewer side effects compared to antibiotic therapy alone. Moreover, research has indicated that cranberry extract, when used alongside clarithromycin, exhibits a synergistic antibacterial effect, underscoring the potential of botanical extracts as complementary therapeutic agents.

Safety and Considerations

While botanical extracts are generally regarded as safe, certain extracts may pose risks at high doses or interact with preexisting medical conditions. Future studies should focus on evaluating the safety and potential toxicity of botanical extracts, particularly in vulnerable populations such as pregnant women, children, and the elderly. For instance, research has indicated that excessive consumption of licorice extract may lead to adverse effects, including alterations in blood pressure and electrolyte balance. Therefore, careful monitoring of dosage and possible side effects is essential when incorporating botanical extracts into H. pylori treatment regimens.

Novel Botanical Extracts for H. pylori Treatment

Broccoli Sprout Extract (BSE)

Derived from young shoots of Brassica oleracea, broccoli sprout extract (BSE) has been recognized for its medicinal properties. It contains several bioactive compounds, such as sulforaphane, glucoraphanin, and indole-3-carbinol, which contribute to its antimicrobial and anti-inflammatory effects. Sulforaphane, a naturally occurring isothiocyanate with the molecular formula $C_6H_{11}NOS_2$, is found in high

concentrations in broccoli sprouts and exhibits potent antibacterial activity against H. pylori. Recent studies have examined BSE as a potential therapy for H. pylori infection, demonstrating that its use alongside standard triple therapy enhances eradication rates. Additionally, BSE has been shown to significantly reduce H. pylori colonization compared to placebo. While the optimal dosage varies depending on formulation and method of administration, research has commonly used doses ranging from 50 mg to 1000 mg per day.

Cranberry Extract (CE)

Cranberry extract (CE), obtained from Vaccinium macrocarpon, has been traditionally valued for its health benefits. It contains various bioactive compounds, including proanthocyanidins, anthocyanins, and flavonols, with proanthocyanidins being the primary component responsible for its anti-H. pylori effects. The molecular formula of proanthocyanidins is $C_{30}H_{26}O_{13}$. The effectiveness of CE in H. pylori management has been explored in multiple studies, with dosages typically ranging from 500 mg to 1500 mg per day. Although CE is generally safe, excessive intake may lead to gastrointestinal discomfort or diarrhea. The extraction process, whether water-based, ethanol-based, or supercritical fluid extraction, can influence the composition and therapeutic potential of cranberry extract.

Garlic Extract (GE)

Extracted from Allium sativum, garlic extract (GE) has been utilized for centuries due to its medicinal benefits. It contains several key bioactive compounds, including allicin, alliin, and diallyl sulfide, known for their antimicrobial and anti-inflammatory properties. Allicin, in particular, has demonstrated strong activity against H. pylori. The recommended daily intake of garlic extract varies depending on its formulation and intended use. Studies have reported doses ranging from 400 mg to 1200 mg per day. While GE is considered safe for most individuals, excessive consumption may result in gastrointestinal discomfort or an increased risk of bleeding. Therefore, adherence to recommended dosages is essential for safe users.

Ginger

Ginger (Zingiber officinale) is a widely used spice and medicinal herb with a long history in traditional medicine. It contains multiple bioactive compounds, including gingerols, shogaols, and paradols. Among these, gingerol is the most significant, known for its strong activity against Helicobacter pylori. The recommended dosage of ginger extract varies based on its intended use, with most studies suggesting a range of 500 mg to 2000 mg per day. While ginger extract is generally recognized as safe, consuming it in high amounts may lead to digestive discomfort or, in some cases, bleeding. Therefore, it is crucial to adhere to the recommended daily intake. Gingerol, a key active compound, has the molecular formula C17H26O4. Ginger extract can be derived through methods such as solvent extraction, steam distillation, and supercritical fluid extraction, each of which influences its composition and biological effectiveness.

Green Tea

Green tea (Camellia sinensis) has been a staple beverage in Asian cultures for centuries and is well-known for its health-promoting properties. Green tea extract offers various benefits, including anti-inflammatory, antioxidant, and antimicrobial effects. It contains several bioactive compounds, such as catechins, epicatechins, and flavonoids. Key catechins found in green tea extract include epigallocatechin gallate (EGCG), epicatechin gallate (ECG), and epicatechin (EC), with EGCG exhibiting notable activity against Helicobacter pylori.

The appropriate dosage of green tea extract varies, but research commonly recommends between 500 mg and 1500 mg per day. While generally safe, excessive consumption may cause gastrointestinal discomfort or liver toxicity. Therefore, staying within the recommended daily limit is advised. EGCG, a major active component, has the molecular formula C22H18O11. Green tea extract is obtained through various methods, including water extraction, ethanol extraction, and supercritical fluid extraction, each affecting its composition and bioactivity.

Licorice

Licorice (Glycyrrhiza glabra) is a perennial herb valued in traditional medicine for its anti-inflammatory, antioxidant, and antimicrobial properties. Its extract contains multiple bioactive compounds, including glycyrrhizin, liquiritigenin, and glabridin. Glycyrrhizin, in particular, is known for its effectiveness against Helicobacter pylori. The recommended dosage of licorice extract varies depending on its intended use, with most studies suggesting between 200 mg and 800 mg per day. While licorice extract is generally considered safe, excessive consumption may lead to high blood pressure, fluid retention, and low potassium levels. To avoid these risks, it is crucial to adhere to the recommended daily intake. The molecular formula of glycyrrhizin is C42H62O16. Licorice extract can be produced using solvent extraction, steam distillation, or supercritical fluid extraction, each method influencing its chemical composition and bioactivity.

Peppermint

Peppermint (Mentha x piperita) is a widely used herb with a long-standing presence in traditional medicine. It is known for its antimicrobial, anti-inflammatory, and analgesic effects. The extract of peppermint contains several active compounds, such as menthol, menthone, and rosmarinic acid. Among these, menthol is particularly effective against Helicobacter pylori. The recommended dosage of peppermint extract varies based on the product and intended use, with most studies suggesting a range of 500 mg to 1500 mg per day. Although peppermint extract is generally regarded as safe, excessive intake may lead to digestive discomfort. To minimize risks, it is essential to stay within the recommended daily dosage. Menthol, one of the primary active constituents, has the molecular formula C10H20O. Various methods, including steam distillation, solvent extraction, and supercritical fluid extraction, can be used to obtain peppermint extract, each influencing its composition and potency.

Turmeric

Turmeric (Curcuma longa), a member of the ginger family (Zingiberaceae), has been widely used for its medicinal benefits, which include anti-inflammatory, antioxidant, and antimicrobial properties. The extract of turmeric contains multiple bioactive components, such as curcuminoids, essential oils, and polysaccharides. The principal curcuminoids in turmeric extract include curcumin, demethoxycurcumin, and bisdemethoxycurcumin, with curcumin demonstrating notable activity against Helicobacter pylori. The optimal dosage of turmeric extract depends on its intended use, with research generally recommending between 500 mg and 2000 mg per day. While turmeric extract is typically safe, consuming it in high amounts may lead to gastrointestinal issues. Therefore, adherence to the suggested daily intake is crucial. Curcumin, a key bioactive compound, has the molecular formula C21H20O6. The extraction of turmeric extract can be performed using various techniques, including solvent extraction, supercritical fluid extraction, and microwave-assisted extraction, each of which affects the final composition and efficacy of the extract.

Wormwood

Wormwood (Artemisia absinthium L.) is a perennial herbaceous plant belonging to the

Asteraceae family. It has a history of traditional medicinal use, particularly for its anti-inflammatory, antipyretic, and antimicrobial effects. Historically, wormwood was a key ingredient in absinthe, a well-known alcoholic beverage from the 19th century. The plant contains numerous bioactive compounds, including sesquiterpene lactones, flavonoids, and essential oils. Key sesquiterpene lactones found in wormwood include absinthin, artemisinin, and anabsinthin, with artemisinin being extensively studied for its anti-malarial properties and emerging potential in combating Helicobacter pylori. The dosage of wormwood extract depends on its specific application, though research typically recommends between 500 mg and 1500 mg per day. However, wormwood also contains thujone, a potentially toxic compound that may cause seizures and other adverse effects in excessive amounts. As a safety measure, the intake of thujone should not exceed 350 mg per day. Artemisinin, one of wormwood's primary active components, has the molecular formula C15H22O5. Wormwood extract can be obtained through methods such as maceration, percolation, and Soxhlet extraction, each of which influences its final composition and biological activity.

Olive

The olive tree (Olea europaea L.) is an evergreen species belonging to the Oleaceae family. Olive extract has gained attention for its potential role in combating Helicobacter pylori, thanks to its bioactive compounds, including oleuropein, hydroxytyrosol, and tyrosol. While the precise dosage for H. pylori eradication remains under investigation, studies have utilized doses ranging from 500 mg to 1000 mg per day, with extracts standardized to contain at least 20% oleuropein.

The primary active compounds in olive extract—oleuropein, hydroxytyrosol, and tyrosol—contribute to its antimicrobial properties. Oleuropein, a secoiridoid glycoside, is most abundant in olive leaves, while hydroxytyrosol and tyrosol, both phenolic compounds, are primarily found in olive fruit. Oleuropein has a molecular formula of C25H32O13 and a molecular weight of 540.5 g/mol, whereas hydroxytyrosol has a formula of C8H10O3 and a molecular weight of 154.16 g/mol.

Olive extract can be produced using different extraction techniques, such as solvent extraction, supercritical fluid extraction, and microwave-assisted extraction. Solvent extraction is commonly employed for olive leaf extract, while supercritical fluid extraction is favored for olive fruit extract due to its higher yield and lower environmental impact.

Novel Botanical Extracts for *H. pylori* Treatment

Broccoli Sprout Extract (BSE)

Derived from young shoots of *Brassica oleracea*, broccoli sprout extract (BSE) has been recognized for its medicinal properties. It contains several bioactive compounds, such as sulforaphane, glucoraphanin, and indole-3-carbinol, which contribute to its antimicrobial and anti-inflammatory effects. Sulforaphane, a naturally occurring isothiocyanate with the molecular formula $C_6H_{11}NOS_2$, is found in high concentrations in broccoli sprouts and exhibits potent antibacterial activity against *H. pylori*.

Recent studies have examined BSE as a potential therapy for *H. pylori* infection, demonstrating that its use alongside standard triple therapy enhances eradication rates. Additionally, BSE has been shown to significantly reduce *H. pylori* colonization compared to placebo. While the optimal dosage varies depending on formulation and method of administration, research has commonly used doses ranging from 50 mg to 1000 mg per day.

Cranberry Extract (CE)

Cranberry extract (CE), obtained from *Vaccinium macrocarpon*, has been traditionally valued for its

health benefits. It contains various bioactive compounds, including proanthocyanidins, anthocyanins, and flavonols, with proanthocyanidins being the primary component responsible for its anti-*H. pylori* effects. The molecular formula of proanthocyanidins is $C_{30}H_{26}O_{13}$. The effectiveness of CE in *H. pylori* management has been explored in multiple studies, with dosages typically ranging from 500 mg to 1500 mg per day. Although CE is generally safe, excessive intake may lead to gastrointestinal discomfort or diarrhea. The extraction process, whether water-based, ethanol-based, or supercritical fluid extraction, can influence the composition and therapeutic potential of cranberry extract.

Garlic Extract (GE)

Extracted from *Allium sativum*, garlic extract (GE) has been utilized for centuries due to its medicinal benefits. It contains several key bioactive compounds, including allicin, alliin, and diallyl sulfide, known for their antimicrobial and anti-inflammatory properties. Allicin, in particular, has demonstrated strong activity against *H. pylori*.

The recommended daily intake of garlic extract varies depending on its formulation and intended use. Studies have reported doses ranging from 400 mg to 1200 mg per day. While GE is considered safe for most individuals, excessive consumption may result in gastrointestinal discomfort or an increased risk of bleeding. Therefore, adherence to recommended dosages is essential for safe usage.

Potential Benefits and Drawbacks of Botanical Extracts in H. pylori Treatment

The use of botanical extracts as a complementary or alternative therapy for H. pylori infection has gained increasing attention due to their natural antimicrobial and anti-inflammatory properties. However, while these extracts offer several potential benefits, they also come with certain limitations.

Potential Benefits

Fewer Side Effects: Unlike conventional antibiotics, which may cause gastrointestinal disturbances such as nausea, vomiting, and diarrhea, botanical extracts are generally well-tolerated and have a lower risk of adverse effects. This makes them a more appealing option for individuals sensitive to antibiotic therapy. Antimicrobial Properties: Several plant-derived compounds have demonstrated inhibitory effects on H. pylori growth. For instance, extracts from garlic, turmeric, ginger, and cinnamon have exhibited antimicrobial activity against H. pylori, suggesting their potential role in alternative treatment strategies. Anti-inflammatory Effects: Many botanical extracts also possess anti-inflammatory properties, which may help alleviate stomach inflammation caused by H. pylori infection. Natural compounds found in licorice, chamomile, and aloe vera, for example, have been shown to reduce gastric inflammation, potentially improving patient outcomes.

Potential Drawbacks

Lack of Standardization: One major challenge in using botanical extracts for H. pylori treatment is the inconsistency in their composition and potency. The effectiveness of plant-based treatments can vary depending on factors such as cultivation methods, extraction processes, and preparation techniques, making it difficult to ensure standardized dosing.

Limited Clinical Evidence: Although preliminary studies have shown promising results, much of the research on botanical extracts for H. pylori has been conducted in laboratory settings or animal models. More large-scale clinical trials in human populations are necessary to establish their efficacy and safety as a reliable treatment option.

Potential Drug Interactions: Some botanical extracts can interact with prescription medications, posing risks for individuals taking multiple drugs. For example, compounds found in St. John's Wort and Ginkgo biloba can interfere with blood

thinners, while grapefruit extract is known to affect the metabolism of certain cholesterol-lowering drugs.

Comparison Between Conventional Chemical Therapy and Herbal Alternatives for H. pylori Treatment

Efficacy

Traditional treatment for H. pylori typically involves a combination of antibiotics and proton pump inhibitors (PPIs), achieving eradication rates of up to 90% in some cases. However, the growing prevalence of antibiotic-resistant H. pylori strains has significantly reduced treatment success rates in certain regions.

Side Effects of Chemical Therapy

While effective, conventional therapy can lead to undesirable side effects, including nausea, diarrhea, vomiting, and abdominal discomfort. Additionally, prolonged use of PPIs has been linked to an increased risk of bone fractures, kidney disease, and infections, raising concerns about long-term safety.

Potential of Herbal Alternatives

Natural remedies such as mastic gum, licorice, and cranberry-derived compounds have demonstrated antimicrobial effects against H. pylori in laboratory and animal studies. However, robust clinical trials are still lacking, making their effectiveness in human populations uncertain. Despite being generally well-tolerated, some herbal treatments may pose risks at high doses or interact with specific health conditions. For example, excessive consumption of licorice has been associated with elevated blood pressure and imbalances in potassium levels.

Weighing the Options

Conventional antibiotic-based therapy remains the gold standard for H. pylori eradication, but concerns over antibiotic resistance and side effects continue to drive interest in alternative approaches. Herbal remedies present a potentially safer option with fewer side effects, though their clinical efficacy is not yet well-established. Further research is needed to determine whether these natural compounds can serve as reliable standalone treatments or adjuncts to conventional therapy.

Utilizing Artificial Intelligence (AI) in the Management of H. pylori

Artificial intelligence (AI) is transforming the search for botanical extracts that may serve as effective treatments for H. pylori infections. Machine learning algorithms can analyze vast datasets of chemical compounds and their biological properties, helping researchers identify potential therapeutic agents. For instance, recent AI-driven research has successfully pinpointed plant-derived compounds with promising antimicrobial properties against H. pylori, offering new avenues for drug development. Beyond compound identification, AI plays a crucial role in refining extraction and purification techniques for bioactive botanical compounds. Traditional extraction methods often rely on trial-and-error adjustments, but AI can optimize this process by systematically testing variables to enhance yield and purity. One study, for example, applied machine learning to improve the extraction of flavonoids from Scutellaria baicalensis, demonstrating that combining ultrasound-assisted extraction with enzymatic hydrolysis produced the most effective results. AI can also predict the biological effects of botanical extracts based on their chemical composition. This capability allows researchers to identify extracts with high therapeutic potential and isolate key bioactive compounds. For instance, AI-based modeling has identified epigallocatechin gallate and quercetin as compounds with significant anti-inflammatory and H. pylori inhibitory effects. Additionally, AI is instrumental in assessing the synergistic interactions between multiple botanical extracts. A recent study utilized machine learning to evaluate the combined antimicrobial effects of Rhizoma

coptidis, Cortex phellodendri, and Radix scutellariae on H. pylori. Using a support vector machine algorithm, researchers determined that the combination exhibited significantly greater antibacterial activity compared to the individual extracts alone. By integrating AI into H. pylori management, researchers can accelerate drug discovery, refine extraction methods, and optimize therapeutic combinations, potentially leading to more effective and personalized treatment strategies.

Future Research Directions in Herbal Medicine for *H. pylori* Treatment

Identification of Active Compounds

Herbal medicines often contain multiple bioactive compounds, making it challenging to pinpoint the specific components responsible for their antimicrobial and anti-inflammatory properties. Future research should focus on isolating and characterizing these active compounds to better understand their role in combating *H. pylori*.

Standardization of Herbal Formulations

The effectiveness of herbal treatments can vary due to differences in plant species, extraction methods, and environmental factors. Establishing standardized protocols for herbal preparations is essential to ensure consistent potency, safety, and therapeutic outcomes.

Clinical Trials and Evidence-Based Research

Currently, there is limited clinical data supporting the use of herbal medicine for *H. pylori* infection. Future studies should prioritize well-structured, randomized controlled trials to assess the efficacy, safety, and potential benefits of herbal therapies in human populations.

Understanding Mechanisms of Action

Further research is needed to explore how herbal compounds exert their antimicrobial and anti-inflammatory effects against *H. pylori*. Investigating molecular pathways and targets involved in these interactions could enhance the development of more effective herbal treatments.

Potential for Combination Therapy

Integrating herbal medicines with conventional antibiotic treatments may improve treatment outcomes and help combat antibiotic resistance. Future studies should evaluate the effectiveness and safety of combination therapy, considering potential interactions and synergistic effects.

Safety and Toxicity Assessment

While herbal medicines are generally regarded as safe, some may have adverse effects at high doses or interact with certain health conditions. Research should focus on assessing the safety and toxicity of herbal treatments, particularly in vulnerable groups such as pregnant women, children, and the elderly. By addressing these research gaps, the field of herbal medicine can move towards evidence-based applications, offering more reliable and effective treatment options for *H. pylori* infection.

CONCLUSION

Recent research highlights the potential of botanical extracts as alternative treatments for Helicobacter pylori infection. Natural compounds found in green tea, broccoli sprout extract, cranberry extract, garlic, ginger, peppermint oil, turmeric root, artemisinin, and licorice have demonstrated antibacterial, anti-inflammatory, and antioxidant properties. While these extracts show promise, further research is necessary to fully understand their effectiveness, possible side effects, and interactions with other medications. Advancements in diagnostic tools, such as non-invasive methods like serology and stool antigen tests, have improved H. pylori detection. Currently, the standard treatment includes a combination of antibiotics and proton pump inhibitors, but the rise of antibiotic resistance has emphasized the need for alternative approaches. Future research should focus on developing more effective and targeted therapies for H. pylori. This includes establishing standardized evaluation methods for botanical extracts and exploring the

benefits of combination therapies. Additionally, artificial intelligence (AI) presents an innovative approach to drug discovery, aiding in the identification of bioactive compounds, predicting their therapeutic potential, optimizing extraction methods, and assessing synergistic interactions among plant-derived treatments. By integrating AI with traditional research methods, scientists can efficiently identify and refine botanical extracts for H. pylori treatment. This combined approach may pave the way for safer and more effective alternatives to conventional antibiotics, ultimately improving patient outcomes and offering new strategies in the fight against H. pylori infections.

Recommendations

To advance the use of botanical extracts in H. pylori treatment, further research is essential to determine their clinical efficacy, optimal dosages, and safety profiles, particularly when combined with standard antibiotic therapy. The integration of artificial intelligence (AI) in compound screening and extraction process optimization offers a promising approach to improving the identification and refinement of bioactive compounds. Additionally, alternative treatment strategies such as phage therapy and novel antibiotics like furazolidone should be explored further to combat antibiotic resistance. Establishing standardized protocols for botanical extracts and conducting larger clinical trials are crucial steps in validating the effectiveness of plant-based therapies for H. pylori infections.

REFRENCES

1. Addissouky, T. A., Ali, M. M., El Sayed, I. E. T., & Wang, Y. (2023). Recent advances in diagnosing and treating Helicobacter pylori through botanical extracts and advanced technologies. Archives of Pharmacology and Therapeutics, 5(1), 53-66.
2. Addissouky, T. A., Wang, Y., El Sayed, I. E. T., Baz, A. E., Ali, M. M., & Khalil, A. A. (2023). Recent trends in Helicobacter pylori management: Harnessing the power of AI and other advanced approaches. Beni-Suef University Journal of Basic and Applied Sciences, 12(1), 80.
3. Liu, Q., Meng, X., Li, Y., Zhao, C. N., Tang, G. Y., Li, S., … & Li, H. B. (2018). Natural products for the prevention and management of Helicobacter pylori infection. Comprehensive Reviews in Food Science and Food Safety, 17(4), 937-952.
4. Parreira, P., Duarte, M. F., Reis, C. A., & Martins, M. C. L. (2016). Helicobacter pylori infection: A brief overview on alternative natural treatments to conventional therapy. Critical Reviews in Microbiology, 42(1), 94-105.
5. Vale, F. F., & Oleastro, M. (2014). Overview of the phytomedicine approaches against Helicobacter pylori. World Journal of Gastroenterology, 20(19), 5594.
6. Vítor, J. M. B., & Vale, F. F. (2011). Alternative therapies for Helicobacter pylori: Probiotics and phytomedicine. FEMS Immunology & Medical Microbiology, 63(2), 153-164
7. Takeuchi, H., Trang, V. T., Morimoto, N., Nishida, Y., Matsumura, Y., & Sugiura, T. (2014). Natural products and food components with anti-Helicobacter pylori activities. World Journal of Gastroenterology, 20(27), 8971.
8. Elbehiry, A., et al. (2023). Helicobacter pylori infection: Current status and future prospects on diagnostic, therapeutic, and control challenges. Antibiotics, 12(2), 191.
9. Rana, R., Wang, L., Li, J., Wang, Y. X., Rao, Q. W., & Yang, C. Q. (2017). Helicobacter pylori infection: A recent approach to diagnosis and management. Journal of Biomedicine, 2, 4.
10. Zhao LY, Mei JX, Yu G, Lei L, Zhang WH, Liu K, et al. Role of the gut microbiota in anticancer therapy: from molecular

mechanisms to clinical applications. Signal Transduct Target Ther. 2023;8(1):201

11. Bashir SK, Khan MB. Overview of Helicobacter pylori infection, prevalence, risk factors, and its prevention. Adv Gut Microbiome Res. 2023;2023:9747027
12. Liu D, Wang Q, Li P, Wu DH, Pan J, Chen ZY, et al. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial. Clin Res Hepatol Gastroenterol. 2023;47(5):102125.
13. Li R, Xu J, Wang X, Liao LJ, Wei X, Xie P, et al. Therapeutic effect of demethylated hydroxylated phillygenin derivative on Helicobacter pylori infection. Front Microbiol. 2023;14.
14. Reyes VE. Helicobacter pylori and its role in gastric cancer. Microorganisms. 2023;11(5):1312.
15. Addissouky TA, Wang Y, El Sayed IE, Baz AE, Ali MM, Khalil AA. Recent trends in Helicobacter pylori management: harnessing the power of AI and other advanced approaches. Beni-Suef University Journal of Basic and Applied Sciences. 2023 Sep 2;12(1):80.
16. Shi Y, Wei N, Wang K, Tao T, Yu F, Lv B, et al. Diagnostic value of artificial intelligence-assisted endoscopy for chronic atrophic gastritis: A systematic review and meta-analysis. Front Med. 2023;10.
17. Dehzad MJ, Ghalandari H, Amini MR, Askarpour M. Effects of curcumin/turmeric supplementation on liver function in adults: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2023;74:102952.
18. Jiang X, Xu C, Liu B, Chen P, Xu Q, Zhang L, et al. Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: A systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):313.
19. Lee B, Ha N, Park H, Kim AR, Kwon OJ, Cho JH, et al. Herbal Medicine Yukgunja-Tang for Functional Dyspepsia: A Protocol for a Randomized, Controlled, Multicenter Clinical Trial. Healthcare (Basel). 2023;11(10):1456.
20. Mosaddad SA, Hussain A, Tebyaniyan H. Green alternatives as antimicrobial agents in mitigating periodontal diseases: A narrative review. Microorganisms. 2023;11(5):1269.
21. Cheng S, Li H, Luo J, Chi J, Zhao W, Lin J, et al. Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: A single-center, randomized, controlled study. Front Microbiol. 2023;14.
22. Goodoory VC, Ford AC. Antibiotics and probiotics for irritable bowel syndrome. Drugs. 2023;83(6):687-699.
23. Syam AF, Miftahussurur M, Makmun D, Abdullah M, Rani AA, Siregar GA, et al. Management of dyspepsia and Helicobacter pylori infection: the 2022 Indonesian Consensus Report. Gut Pathog. 2023;15(1):25.
24. Johnson MC, Laderman E, Huiting E, Zhang C, Davidson A, Bondy-Denomy J. Core defense hotspots within Pseudomonas aeruginosa are a consistent and rich source of anti-phage defense systems. Nucleic Acids Research. 2023 Jun 9;51(10):4995-5005
25. Ngashangva L, Chattopadhyay S. Biosensors for point-of-care testing and personalized monitoring of gastrointestinal microbiota. Front Microbiol. 2023;14:1114707.
26. Syam AF, Miftahussurur M, Makmun D, Abdullah M, Rani AA, Siregar GA, et al. Management of dyspepsia and Helicobacter

pylori infection: the 2022 Indonesian Consensus Report. Gut Pathog. 2023;15:25.
27. Rattanachaisit P, Burana C, Jaroenlapnopparat A, Vongseenin S, Chaithongrat S, Rerknimitr R, et al. The prevalence and treatment outcomes of Helicobacter pylori infection in a tertiary hospital in Thailand, 2018-2021. JGH Open. 2023 May 26;7(6):439-444.
28. Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere Groza F, et al. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics. 2022;12(2):508.
29. Olson L, Christensen E. For patients with Helicobacter pylori infection, is whole-family treatment more effective than single-patient treatment at preventing recurrence?. Evidence-Based Practice. 2023 Oct 1;26(10):7-8.
30. Jaradat H, Ibbini M, Fourati N, Kanoun O. Novel Sensitive Electrochemical Immunosensor Development for the Selective Detection of HopQ H. pylori Bacteria Biomarker. Biosensors. 2023;13(5):527.
31. Chen MJ, Chen PY, Fang YJ, Bair MJ, Chen CC, Chen CC, et al. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):623-634.
32. Wang X, Gong Y, He L, Zhao L, Wang Y, Zhang J, et al. Clinical relevance and distribution of Helicobacter pylori virulence factors in isolates from Chinese patients. Ann Transl Med. 2023;11(8):301.
33. Garcés-Durán R, Llach J, Da Fieno A, Córdova H, Fernández-Esparrach G. Endoscopic diagnosis of H. pylori infection. Gastroenterol Hepatol. 2023 Jun-Jul;46(6):483-488. English, Spanish.
34. Kim I, Maeng LS, Kim JS, Kim BW, Cheung DY, Kim JI, et al. Quantitative multiplex real-time polymerase chain reaction assay for the detection of Helicobacter pylori and clarithromycin resistance. BMC Microbiol. 2023;23:155.
35. Chen J, Guo Y, Huang Y, Ding Z, Wang J, Liang X, et al. Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial. J Infect Dis. 2023 Aug 31;228(5):511-518.

HOW TO CITE: Chordiya Divya*, Vaishnavi Bansode, Rohit Bhosale, Azeem Mannan Bagwan, Recent Advancement in Management of H. Pylori Induced PUD, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 3, 520-534. https://doi.org/10.5281/zenodo.14993138